Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma’s ambitious pipeline touches dozens of rare genetic diseases, which means each SEC document is dense with trial data, cash-runway tables and licensing terms. If you have ever typed “BridgeBio Pharma SEC filings explained simply” or hunted through a 200-page report for one orphan-drug update, you know how time-consuming it can be.
Stock Titan solves that problem. Our AI engine turns the company’s most complex disclosures into plain-language insights. Open a BridgeBio Pharma annual report 10-K simplified or drill into a BridgeBio Pharma quarterly earnings report 10-Q filing—key figures, pipeline timelines and risk factors are highlighted automatically. Material news drops? A BridgeBio Pharma 8-K material events explained alert lands in your dashboard within seconds. Need trading color? We stream BridgeBio Pharma Form 4 insider transactions real-time so you never miss executive stock moves.
Here’s what you can uncover in seconds:
- Cash usage trends and dilution impact through BridgeBio Pharma earnings report filing analysis.
- Pipeline milestones linked to specific clinical programs, flagged across multiple forms.
- BridgeBio Pharma executive stock transactions Form 4 and broader insider trading Form 4 transactions for sentiment checks.
- BridgeBio Pharma proxy statement executive compensation details, including option grants and performance metrics.
Whether you’re understanding BridgeBio Pharma SEC documents with AI for the first time or monitoring seasoned positions, every filing type—10-K, 10-Q, 8-K, S-1, SC 13D and more—updates in real time from EDGAR. Spend less time scrolling and more time acting on the genetic-medicine data that moves the market.
BridgeBio Pharma director Ronald J. Daniels received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct RSU ownership to 16,991 units
- 8,425 Stock Options with an exercise price of $41.73 per share
Both grants follow a 3-year vesting schedule with one-third vesting annually from June 20, 2025 through June 20, 2028, contingent on continued board service. The stock options expire on June 19, 2035. These grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation aligned with long-term shareholder interests.
BridgeBio Pharma Director Ali J. Satvat reported two significant equity transactions on June 20, 2025:
- Received 6,589 restricted stock units (RSUs) at $0, bringing total direct ownership to 165,993 shares. RSUs vest over three years through June 20, 2028
- Granted stock options to purchase 8,425 shares at an exercise price of $41.73 per share, expiring June 19, 2035
Both grants are subject to continued service on the board and follow a three-year vesting schedule, with one-third vesting each year starting June 20, 2025. The transactions were executed under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Satvat serves as a Director but is not a 10% owner of BridgeBio Pharma.
BridgeBio Pharma director Charles J. Homcy received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, vesting over 3 years through June 20, 2028
- 8,425 Stock Options with an exercise price of $41.73, vesting over 3 years through June 20, 2028
Following these transactions, Homcy directly owns 1,236,674 shares of common stock. Both the RSUs and stock options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing represents standard board member equity compensation.
BridgeBio Pharma Director Fred Hassan received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 25,889 shares
- 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Hassan's continued service as a director. The awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing was signed on June 24, 2025, within the required reporting window.
BridgeBio Pharma Director Douglas A. Dachille reported multiple equity transactions on June 20, 2025:
- Received 6,589 restricted stock units (RSUs) with $0 exercise price, vesting over three years through June 20, 2028
- Granted 8,425 stock options with strike price of $41.73, vesting over three years and expiring June 19, 2035
- Currently holds 20,000 shares indirectly through The Dachille 2012-1 Family Trust for his children's benefit
All equity grants are subject to continued service on BridgeBio's board of directors. The RSUs and options will vest in three equal annual installments starting June 20, 2025. These grants appear to be part of the company's standard director compensation under their 2021 Amended and Restated Stock Option and Incentive Plan.
BridgeBio Pharma Director Hannah Valantine reported multiple equity transactions on June 20, 2025:
- Received 6,589 Restricted Stock Units (RSUs) at $0 cost, vesting over three years through June 20, 2028
- Granted 8,425 stock options with strike price of $41.73, exercisable until June 19, 2035
- Options and RSUs vest in three equal annual installments starting June 20, 2025
Following these transactions, Valantine's holdings include:
- Direct ownership: 8,353 common shares and 8,425 stock options
- Indirect ownership: 3,433 shares held by spouse
These grants appear to be part of standard director compensation under the company's 2021 Amended and Restated Stock Option and Incentive Plan. All vesting is contingent on continued board service.
BridgeBio Pharma Director Randal W. Scott reported significant equity compensation grants on June 20, 2025. The transactions include:
- 6,589 Restricted Stock Units (RSUs) granted at $0, vesting over three years through June 20, 2028
- 8,425 Stock Options awarded with an exercise price of $41.73, vesting over three years through June 20, 2028
Following these transactions, Scott's holdings include 11,589 shares held directly and 4,000 shares held indirectly through Thinking Bench Capital LLC. Both the RSUs and stock options are subject to continued service on the board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation arrangements.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
What is BridgeBio Pharma's core business?
How does BridgeBio Pharma differentiate itself from other biopharmaceutical companies?
What types of diseases does BridgeBio focus on?
What is the significance of the portfolio-based strategy employed by BridgeBio?
How does BridgeBio Pharma ensure the credibility of its drug development programs?
What role does genetic innovation play in BridgeBio's strategy?
How is BridgeBio Pharma positioned within the competitive biopharmaceutical market?
What kind of expertise supports BridgeBio Pharma's operations?
